DR. LORI J. WIRTH, MD

Plain English
This study focused on a specific genetic mutation in cancer patients that affects the p53 protein, which normally helps prevent tumor growth. Researchers found that about 1.8% of tumors with a Y220C mutation developed additional changes that made them resistant to a new drug called rezatapopt, which was initially effective. By identifying these resistance mechanisms, the study helps develop better strategies to treat patients with this mutation in the future. Who this helps: This helps cancer patients with the Y220C mutation in the TP53 gene.

Plain English
This study looked at how some advanced cancers with specific genetic changes (known as RET alterations) can develop resistance to new treatments called selective RET inhibitors (SRI), specifically selpercatinib and pralsetinib. Researchers analyzed tissue and blood samples from 109 patients who received these treatments, finding that while only 14% had new mutations in the RET gene itself, a more common issue was the emergence of other gene changes, particularly involving a gene called MET. The study showed that patients experienced an average of about 14 months without their cancer progressing after starting SRI treatments, which provides insight into how treatments can be improved. Who this helps: This helps patients with RET-altered cancers and their doctors by identifying potential resistance mechanisms that could lead to better therapies.

Plain English
Researchers developed an artificial intelligence tool that predicts whether head and neck cancer patients will have cancer return or die within the next five years after surgery, using patient information like age, tumor characteristics, and blood test results collected over time. The AI tool was 70-80% accurate at making these predictions across different time points, and worked especially well for a specific type of throat cancer caused by HPV (93% accurate at one year). This matters because doctors can now identify patients at high risk of recurrence or death earlier, allowing them to adjust treatment plans—either intensifying care for those most likely to relapse or reducing harsh treatments for those with better odds.

Plain English
This study looked at how well a drug called selpercatinib works for patients with RET-mutant pheochromocytoma, a type of tumor. Out of six patients treated, four showed improvement in their condition, with some remaining stable for over 56 months. This is important because it shows that selpercatinib can be an effective treatment option for patients with this specific type of tumor. Who this helps: Patients with RET-mutant pheochromocytoma, especially those with familial MEN2 syndromes.

Plain English
This study looked at the side effects experienced by patients undergoing treatment for advanced thyroid cancer. It found that common issues include fatigue, high blood pressure, and skin problems, with severe side effects like blood clots also being a concern. Managing these side effects effectively is crucial for enhancing patients' quality of life and treatment outcomes. Who this helps: This benefits patients with advanced thyroid cancer.

Plain English
This study examines updated guidelines for treating different types of thyroid cancer, including papillary and medullary carcinoma. The guidelines come from a panel that meets each year to review new research and refine treatment recommendations. These updates are crucial because they help ensure that patients receive the most effective therapies according to the latest evidence. Who this helps: Patients with thyroid cancer and their doctors.

Plain English
This study looks at hereditary thyroid cancer syndromes, particularly medullary thyroid cancer, and explores genetic factors that contribute to these conditions. It emphasizes the importance of genetic testing and personalized treatment plans, noting that specific genetic mutations can help predict cancer risks and improve patient care. Understanding these findings can lead to better management strategies and outcomes for patients with a family history of thyroid cancer. Who this helps: Patients with hereditary thyroid cancer and their families.

Plain English
This study compared how well patients tolerated two cancer treatments: selpercatinib and a combination of cabozantinib and vandetanib, specifically for those with advanced medullary thyroid cancer. Results showed that only 8% of patients on selpercatinib experienced a high burden of side effects, compared to 24% for the other treatments. Additionally, patients on selpercatinib reported fewer issues with quality of life, including less fatigue and diarrhea. Who this helps: This benefits patients with advanced medullary thyroid cancer seeking effective treatment with fewer side effects.

Plain English
This study focuses on updated guidelines for managing differentiated thyroid cancer (DTC) in adult patients, which is the most common type of thyroid cancer in the U.S. The American Thyroid Association (ATA) revised its recommendations to ensure they are based on the latest research and input from a wide range of experts, including patient advocates. These guidelines cover all aspects of care from diagnosis to treatment and monitoring, aiming to enhance patient outcomes and address areas where more research is needed. Who this helps: This benefits doctors and adult patients diagnosed with differentiated thyroid cancer.

Plain English
This study looked at how external magnetic fields affect the movement of carbon atoms in iron at high temperatures. Researchers found that applying a magnetic field can slow down carbon diffusion in iron significantly, matching previous measurements. Understanding this process is important because controlling carbon movement can improve the properties of steel and other iron-based materials. Who this helps: This helps steel manufacturers and engineers working to enhance the quality and durability of iron products.

Plain English
This research paper looks at new treatments targeting a protein called EGFR in patients with head and neck cancer. It discusses the limited effectiveness of current therapies like cetuximab, especially in patients with HPV-positive tumors. However, it also highlights promising new combinations and therapies that could improve outcomes for these patients. Who this helps: This benefits patients with head and neck cancer, particularly those whose cancer is difficult to treat.

Plain English
This study examined how certain structures in the tumor called tertiary lymphoid structures (TLS) can help predict which patients with head and neck cancer will respond to a specific type of immunotherapy known as immune checkpoint blockade (ICB). Researchers looked at tumor samples from 20 patients, finding that those who responded to treatment had more B cells present and better survival rates when TLS were located close to the tumor. The study also showed that measuring TLS density could predict treatment response with 80% accuracy, suggesting it may be a better indicator than the currently used marker. Who this helps: This helps patients with recurrent head and neck cancer by improving treatment prediction and outcomes.

Plain English
Researchers studied how changes in blood samples containing tumor DNA could help predict how well patients with advanced head and neck cancer respond to treatment and how long they might live. They found that when patients had lower levels of this tumor DNA during treatment, they were more likely to respond positively and have better survival rates. This is important because using this DNA information could help doctors make better treatment decisions, potentially improving outcomes for patients.

Plain English
Researchers studied patients with a severe type of head and neck cancer that often comes back or spreads. They found that monitoring a specific marker in the blood, known as circulating tumor DNA (ctDNA), can help predict how well patients will respond to treatment and how long they might live. This is important because it offers a new way to tailor treatments to individual patients, potentially improving their chances of survival and minimizing side effects from ineffective therapies.

Plain English
Adenoid cystic carcinoma (ACC) is a deadly cancer that doesn't respond well to current treatments because tumors hide from the immune system—they have very low levels of a protein called HLA class I that the immune system needs to recognize and attack cancer cells. Researchers discovered that treating ACC tumors with immune-activating drugs called STING agonists can turn this protein back on, and when they tested this approach in one patient combined with an existing immunotherapy drug, the tumor shrank by 70%. This finding suggests that turning HLA class I back on with STING agonists could finally make immunotherapy work for ACC patients.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
This study looked at how patients with a specific type of thyroid cancer, called radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC), were treated in the US and outside the US. Of 647 patients, 478 chose to monitor their cancer without immediate treatment, while 169 started taking medication called multi-kinase inhibitors (MKIs). The results showed that those actively monitored had a 36-month rate of remaining symptom-free of around 66% regardless of their location, while those who switched to MKI treatment later had lower rates of staying symptom-free (30.8% in the US and 55.8% in non-US). Finding the right timing for treatment matters because it helps doctors decide when to start medication for the best possible outcomes. Who this helps: This helps patients with RAI-R DTC and their doctors by providing insights on treatment timing.

Plain English
This study focused on predicting the melting temperatures of certain solid materials, specifically binary ionic compounds, which are important for designing new materials. Researchers combined two types of machine learning techniques to analyze data from 476 materials, ultimately improving prediction accuracy and interpretability; the new method could lower prediction errors significantly from around 180 Kelvin to better results. This research is important because it helps scientists understand how different materials behave under heat, leading to better material design and application. Who this helps: This benefits materials scientists and engineers working on developing new materials.

Plain English
This study looked at the drug vandetanib to see how well it works for patients with advanced thyroid cancer that did not respond to previous treatment with radioactive iodine. Out of 235 patients, those taking vandetanib had a median time without disease progression of 10 months, compared to 5.7 months for those taking a placebo. However, more patients on vandetanib experienced serious side effects and there were more deaths in that group, with 28.2% of vandetanib patients dying compared to 13.6% on the placebo. Who this helps: This research helps doctors understand the effectiveness and risks of treating advanced thyroid cancer with vandetanib.

Plain English
The research focuses on medullary thyroid carcinoma (MTC), a rare type of thyroid cancer. Findings show that early surgery is crucial for curing MTC, and that certain molecular tests can help predict patient outcomes and treatment needs. New approaches, including targeted therapies and active monitoring, have improved patient survival rates and treatment effectiveness. Who this helps: This helps patients with medullary thyroid carcinoma and their doctors in making better treatment decisions.

Plain English
This study looked at how well two drugs, pembrolizumab and lenvatinib, work together for patients with a type of thyroid cancer that doesn’t respond to standard treatments. In one group of patients who had not yet received lenvatinib, about 66% had their cancer shrink, and they lived without disease progression for an average of nearly 27 months. In another group already on lenvatinib, only 16% responded, with an average progression-free survival of 10 months. These findings are important as they suggest that combining these two drugs can help improve treatment outcomes for certain patients with this challenging cancer. Who this helps: This research benefits patients with advanced thyroid cancer that does not respond to radioiodine treatment.

Plain English
This study looked at two targeted therapies, larotrectinib and entrectinib, for patients with lung and thyroid cancers that have a specific genetic change called NTRK fusion. The researchers found that both treatments work well, with larotrectinib and entrectinib showing a high success rate in managing tumors—especially in a form of lung cancer called metastatic adenocarcinoma—making them better options than immunotherapy. Some side effects noted include dizziness and weight gain, but these therapies are valuable for patients whose cancers do not respond to other treatments. Who this helps: This helps patients with NTRK fusion-positive lung and thyroid cancers.

Plain English
This study looked at the long-term effects of a drug called selpercatinib in patients with certain types of thyroid cancer that have specific genetic changes. Researchers found that 82.5% of patients with previously untreated medullary thyroid cancer (MTC) responded well to the treatment, and for those with untreated thyroid cancer (TC), the response rate was even higher at 95.8%. Additionally, many patients lived without their cancer worsening for significant periods, with a three-year survival rate of 75.2% for those with MTC and 87.3% for those with TC. Who this helps: This benefits patients with specific types of thyroid cancer looking for effective treatment options.

Plain English
This study looked at a treatment combining two chemotherapy drugs (gemcitabine and carboplatin) with a special immune therapy using patients' own immune cells to fight recurrent or metastatic nasopharyngeal carcinoma (a form of cancer). Researchers found that the combination treatment had a median overall survival of 25.0 months, slightly higher than the 24.9 months for the chemotherapy alone, but this difference was not statistically significant. Importantly, the combination therapy showed a good safety profile, with minimal serious side effects, but did not significantly improve survival rates compared to standard chemotherapy. Who this helps: This research benefits patients with recurrent or metastatic nasopharyngeal carcinoma looking for advanced treatment options.

Plain English
This research reviewed oncocytic thyroid carcinoma, a rare type of thyroid cancer that makes up about 5% of all thyroid cancers. The study found that this cancer has unique genetic features and behaves differently than other thyroid cancers, including higher chances of spreading to lymph nodes and not responding well to radioiodine treatment. Recognizing these differences is crucial for creating better treatment plans tailored specifically for patients with oncocytic thyroid carcinoma. Who this helps: This helps patients with oncocytic thyroid carcinoma and their doctors in managing their treatment effectively.

Plain English
This study looked at how a new treatment for aggressive thyroid cancer can help restore function to the recurrent laryngeal nerve (RLN), which is important for voice and breathing. In six patients with nerve paralysis, those who received this treatment saw their nerve function return, with an average recovery time of three months. All recovered nerves showed normal structure, suggesting that damage from cancer can be reversed. Who this helps: This benefits patients with thyroid cancer and nerve paralysis looking for improved quality of life after treatment.

Plain English
This study looked at how a special treatment called neoadjuvant therapy can help patients with advanced thyroid cancer have surgery more successfully. Out of 17 patients treated, 11 were able to have surgery, and 10 had no remaining cancer after the operation, showing that the treatment improved surgical outcomes. This matters because it suggests that neoadjuvant therapy can make surgery safer and more effective for these patients, although not everyone benefits equally. Who this helps: Patients with advanced thyroid cancer.

Plain English
This study looked at how certain immune cells in head and neck cancer tumors can predict whether patients will respond well to a treatment called immune checkpoint blockade (ICB). The researchers found that patients who responded to ICB had a higher amount of B lymphocytes (CD20+ cells) in their tumors compared to those who did not respond (22% vs. lower levels). Additionally, certain structures called Tertiary Lymphoid Structures (TLS) near the tumors were linked to better survival rates, with a 4% higher chance of overall survival among patients with these structures. Who this helps: This research helps patients with head and neck cancer by identifying better predictors of treatment response.

Plain English
Researchers looked at 5,030 thyroid cancer samples and found 17 tumors with mutations in a specific gene family—11 where this mutation was the main cancer driver and 6 where it was a secondary mutation that might help cancer resist treatment. They discovered that some of these mutations could be targeted with existing drugs, but doctors aren't currently looking for them because they're not well-known. This matters because identifying these mutations in thyroid cancer patients could open up new treatment options that don't work for other types of thyroid cancer, potentially improving outcomes for people who have these specific mutations.

Plain English
This study looked at how specific biological markers in patients with head and neck cancer treated with pembrolizumab can predict how well they will respond to the treatment. Researchers analyzed data from 257 patients and found that higher levels of certain markers—specifically TMB (tumor mutational burden), PD-L1, and T-cell-inflamed gene expression—were linked to better treatment responses. For example, patients showing high levels of these markers had a significantly higher rate of treatment response compared to those with lower levels. Who this helps: This benefits patients with head and neck cancer by helping doctors predict who is more likely to respond well to pembrolizumab treatment.

Plain English
This study looked at how thyroid cancer can become resistant to treatment over time, specifically focusing on certain genetic changes that affect the effectiveness of drugs designed to target these cancers. The researchers found that when patients initially respond to treatments, they can eventually develop resistance, which makes tumors grow again. Identifying these resistance mechanisms early on can help doctors choose new, more effective treatment options to improve patient outcomes. Who this helps: This benefits thyroid cancer patients and their doctors.

Plain English
This research paper looks at improvements in how medullary thyroid cancer (MTC) is diagnosed and treated. The study found that testing for specific genetic changes (RET testing) has made a big difference in treatment choices, leading to better outcomes; for example, new drugs like selpercatinib and pralsetinib can help patients live longer without their cancer worsening. These developments matter because they provide more targeted and effective treatment options for individuals with this rare type of cancer. Who this helps: This helps patients with medullary thyroid cancer and their doctors.

Plain English
This research paper focuses on thyroid cancers with a specific genetic change called NTRK gene fusions. Researchers found that these fusions are rare but important because they can be treated with targeted therapies that have been approved for advanced thyroid cancers. The paper recommends that doctors should test for these gene fusions early in the process for patients who have hard-to-treat cancers or those that have spread, to determine if they can benefit from these newer treatments. Who this helps: Patients with advanced thyroid cancer who may be eligible for targeted therapies.

Plain English
This study examined the brain activity related to stress in 240 patients with head and neck cancer to see if it could predict how long they would survive. Researchers found that patients with high levels of activity in a brain area called the amygdala had a 2.5 times higher risk of dying compared to those with lower activity, and their time without progression of the disease was shorter—25 months for high-activity patients versus 36.5 months for others. This matters because it shows that measuring amygdala activity can provide important information about cancer prognosis, potentially helping direct patient care. Who this helps: Patients with head and neck cancer.

Plain English
This study examined the effectiveness of a drug called selpercatinib in treating advanced medullary thyroid cancer compared to two other existing treatments, cabozantinib and vandetanib. The results showed that patients taking selpercatinib had a much longer time without their disease worsening; after 12 months, 86.8% of selpercatinib patients were still progression-free compared to only 65.7% of those on the other treatments. Additionally, 69.4% of patients on selpercatinib responded positively to treatment, while only 38.8% on the other medications did. Who this helps: This research benefits patients with advanced medullary thyroid cancer, as they may have a more effective treatment option.

Plain English
Researchers studied a type of thyroid cancer called Hürthle cell carcinoma, which has specific genetic changes that affect energy production in cells. They discovered that these cancer cells are particularly vulnerable to stress from certain harmful molecules due to their genetic makeup. This finding is important because it could lead to new treatments that target this weakness, potentially improving outcomes for patients with this type of cancer.

Plain English
This study looked at two treatment options for patients with a specific type of advanced thyroid cancer that has a BRAF mutation and doesn't respond to radioactive iodine therapy. Researchers divided 53 patients into two groups: one received dabrafenib alone, while the other received dabrafenib along with trametinib. The findings showed that 42% of patients on just dabrafenib experienced a beneficial response, compared to 48% who received both drugs, indicating no significant difference in effectiveness, since both rates were similar. Who this helps: Patients with advanced thyroid cancer that has certain mutations.

Plain English
This study looked at a rare side effect called chylous effusions that can occur in patients taking RET tyrosine kinase inhibitors (TKIs) for cancer. Among nearly 7,600 patients, about 7% of those treated with the drug selpercatinib experienced this issue, while it was less common with other drugs. Recognizing this side effect is important because it helps doctors avoid mistakenly thinking that the patient's cancer is getting worse when it's actually just a reaction to the treatment. Who this helps: This helps patients undergoing treatment with RET TKIs and their doctors.

Plain English
This study focuses on different types of thyroid cancer and their recommended treatments. It found that while most differentiated thyroid cancers (like papillary and follicular) have a good outlook and are mainly treated with surgery and radioactive iodine, other types like anaplastic thyroid cancer are very aggressive and not treatable with the same methods. The guidelines provide clear recommendations on how these cancers should be managed, which is crucial for improving patient outcomes. Who this helps: This helps patients with thyroid cancer and their doctors in choosing the best treatment options.

Plain English
This study looked at how well current risk models predict heart-related problems (ASCVD events) in patients who received radiation therapy for head and neck cancer. Researchers tracked 723 patients and found that while the models predicted fewer events than actually occurred, with 17% experiencing ASCVD events—68% more than expected. This is important because it shows that these risk calculators do not accurately assess the heart risk for these patients, suggesting they might need closer monitoring and preventive care. Who this helps: This helps patients undergoing radiation therapy for head and neck cancer.

Plain English
This research studied the effectiveness of a drug called selpercatinib in patients with advanced medullary thyroid cancer (MTC) who had never been treated with multikinase inhibitors. The trial compared selpercatinib to two other drugs, cabozantinib and vandetanib, to see which one helped patients live longer without their cancer worsening. The results showed that selpercatinib significantly improved progression-free survival, making it a promising option for these patients. Who this helps: This research benefits patients with advanced medullary thyroid cancer.

Plain English
This research focused on a specific genetic change called a fusion in a young woman with a rare and aggressive form of papillary thyroid cancer that had spread throughout her body. The patient was treated with a drug called alectinib, and within eight weeks, she showed significant improvement—her tumors shrunk and her cancer markers dropped dramatically. This finding is important because it shows that identifying these genetic changes can lead to effective treatment options in patients with hard-to-treat thyroid cancer. Who this helps: This helps patients with advanced papillary thyroid cancer and their doctors in selecting targeted treatments.